Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Ads For New Drugs Would Require FDA Preclearance Under Rx Safety Bill

Executive Summary

Promotional materials for recently-approved drugs would receive special scrutiny by the Center for Postmarket Drug Evaluation & Research proposed in Senate legislation

You may also be interested in...



Senior FDA Staff Has Final Say Over Disputes In Enzi/Kennedy Drug Safety Bill

Senior FDA officials will have final say over drug safety disputes under proposed legislation from Sens. Michael Enzi (R-Wyo.) and Edward Kennedy (D-Mass.)

Senior FDA Staff Has Final Say Over Disputes In Enzi/Kennedy Drug Safety Bill

Senior FDA officials will have final say over drug safety disputes under proposed legislation from Sens. Michael Enzi (R-Wyo.) and Edward Kennedy (D-Mass.)

Enzi/Kennedy Drug Safety Bill Will Expand FDA’s Oversight Armamentarium

Drug safety legislation from Senate Health Committee Chairman Michael Enzi (R-Wyo.) will make FDA's enforcement authority more subtle than merely having the ability to pull drugs from the market

Related Content

Topics

UsernamePublicRestriction

Register

LL1134044

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel